Zydus Lifesciences Ltd.
Stock Scores
82.4 / 100
56.4 / 100
83.1 / 100
93.8 / 100
Key Metrics
Stock Analysis
Fundamental analysis overview of Zydus Lifesciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Strong price momentum
Price Momentum score of 83.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
83.1 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 1.5% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
High and stable ROE
The company reported strong ROE of 19.74% for 12-month ended 30 Jun 2026 and ROE declined marginally by -93 bps from 1 year ago
What is ROE (FY)?
Strong revenue growth and above median growth of industry
The company delivered strong revenue growth of 21.11% for 12-month ended 30 Jun 2026 and the growth was 10.43 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Consistently pays dividend
The company has not missed dividend payments once in the last 5 financial years
What is Dividend streak?
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -1.27% for 12-month ended 30 Jun 2026 and the growth was 8.72 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.09%
What is Dividend yield?
Stock appears expensive but is at a discount to industry median P/E
PE TTM of 25.0 indicates that the stock is expensive on a standalone basis but discount to industry median P/E is decent at -21.56%
What is P/E Ratio?
High operating margin but declining trend
The company reported strong operating margin of 18.58% for 12-month ended 30 Jun 2026 but operating margin declined by -632 bps from 1 year ago
What is Operating profit margin?
Low Debt to Equity but increasing
The company has low Debt to Equity of 0.46 as on 30 Jun 2026 but Debt to Equity increased by 0.33 in the last 1 year
What is Debt to Equity?
Company's earnings are of moderate quality
Earnings quality score of 36.0 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
36.0 / 100
Financial Snapshot
See detailed analysisMulti-year trends for Zydus Lifesciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Holdings and Presence
Indices and prominent investors with a stake in this stock.
| # | Index | Weight | Rank |
|---|---|---|---|
| 1 | SHI: Biotech | 17.03% | 1 / 15 |
| 2 | Nifty Pharma | 2.92% | 11 / 20 |
| 3 | Nifty Alpha Low Vol 30 | 2.79% | 25 / 30 |
| 4 | Nifty Healthcare | 2.55% | 14 / 20 |
| 5 | Nifty100 Quality 30 | 1.91% | 28 / 30 |
| 6 | Nifty Next 50 | 1.18% | 43 / 50 |
| 7 | Nifty 100 Equal Weight | 1% | 51 / 100 |
| 8 | Nifty 100 | 0.22% | 93 / 100 |
| 9 | Nifty 500 | 0.15% | 145 / 496 |
| 10 | Nifty Total Market | 0.14% | 147 / 746 |
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Zydus Lifesciences Ltd. shares as reported to NSE and BSE.
| Name | Month | Transaction | Holding % pre transaction | Average price | Qty. | Transaction value |
|---|---|---|---|---|---|---|
Jasodaben Babubhai Patel Promoter Group | November-2025 | Market Purchase (Acquisition) 17th Nov 2025 | 0.00 % | ₹ 963.52 | 1.00 k | ₹ 9.64 lac |
Zydus Family Trust Promoter | March-2024 | Market Sale (Disposal) 29th Mar 2024 | 74.97 % | ₹ 1,006.68 | 10.00 k | ₹ 1.01 cr |
Zydus Family Trust Promoter | March-2024 | Market Sale (Disposal) 29th Mar 2024 | 74.97 % | ₹ 1,010.62 | 30.00 k | ₹ 3.03 cr |
DEVAL DHIRAJBHAI SHAH Employees Immediate Relative | March-2024 | Market Sale (Disposal) 29th Mar 2024 | 0.00 % | ₹ 1,006.64 | 292.00 | ₹ 2.94 lac |
DEVAL DHIRAJBHAI SHAH Employees Immediate Relative | March-2024 | Market Sale (Disposal) 28th Mar 2024 | 0.00 % | ₹ 1,010.92 | 150.00 | ₹ 1.52 lac |
DEVAL DHIRAJBHAI SHAH Employees Immediate Relative | March-2024 | Market Sale (Disposal) 28th Mar 2024 | 0.00 % | ₹ 985.57 | 500.00 | ₹ 4.93 lac |
Zydus Family Trust Promoter | March-2024 | Market Sale (Disposal) 28th Mar 2024 | 75.02 % | ₹ 1,015.35 | 17.53 k | ₹ 1.78 cr |
Zydus Family Trust Promoter | March-2024 | Market Sale (Disposal) 28th Mar 2024 | 75.02 % | ₹ 1,008.66 | 5.65 lac | ₹ 57.04 cr |
HARSHA JYOTINDRA GOR Designated Person | March-2024 | Market Sale (Disposal) 27th Mar 2024 | 0.00 % | ₹ 1,009.07 | 1.00 k | ₹ 10.09 lac |
Vishal J. Gor Designated Person | March-2024 | Market Sale (Disposal) 22nd Mar 2024 | 0.00 % | ₹ 965.98 | 862.00 | ₹ 8.33 lac |
Corporate Actions
History of Zydus Lifesciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
- Dividend₹ 1/shareRecord date: 24th Jul 2026Ex-date: 24th Jul 2026Announced on: 19th May 2026
- OthersEx-date: 29th May 2026Announced on: 19th May 2026On market tender offer
- Dividend₹ 11/shareRecord date: 25th Jul 2025Ex-date: 25th Jul 2025Announced on: 20th May 2025
- Dividend₹ 3/shareRecord date: 26th Jul 2024Ex-date: 26th Jul 2024Announced on: 17th May 2024
- OthersEx-date: 23rd Feb 2024Announced on: 9th Feb 2024"On Market Tender Offer."
Company Profile
Overview of Zydus Lifesciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.